Pharmacovigilance post-Brexit - simpler than previously thought?
To meet new PV regulations, the industry has to face a "multitude of unknowns and an ever-moving target".
Last week, MPs backed an amendment that will keep the UK in the European medicines regulatory network. In a series of industry comment, Part I is provided by David Hukin, head of pharmacovigilance at Quanticate, who highlights what this means for the wider industry.
"A key consideration for the pharma industry when it comes to Brexit is pharmacovigilance (PV). The current situation is that, from 30 March 2019, pharmacovigilance activities, which must take place in an EU member state (or other EEA territory), will no longer be able to be conducted in the UK.
"There is very little time to prepare for what the pharmaceutical industry will look like post-Brexit and it is likely that it will affect companies and sponsors at a wider business level. As we move forward, it is vital that the industry carefully monitors output from the EMA and UK MHRA to guide their strategy. The concerns surrounding Brexit and its impact on the wider industry, including the registration, manufacture and supply of medicines, mean that it will be all too easy for companies to take their eye off the ball when it comes to ensuring they meet the new PV regulations, so it is vital that departments ensure the necessary changes are made.
"In preparing for this, however, we are faced with a multitude of unknowns and an ever-moving target. On 17 July, parliament voted on an amendment tabled by Phillip Lee MP to require the government to negotiate an agreement with the EU for the UK to participate in and align with Europe on medicines regulations and framework.
"The government lost this vote (against the amendment) and so this is significant for PV and access to medicines in general as it could mean the UK remains much more tightly aligned to EU than in other areas. What that means regarding the licensing of medicines and alignment/co-operation on a range of PV factors is still unknown.
"Clarification on the following EU-led initiatives will need to be considered in the negotiations between the EU and UK:
"The Parliamentary vote to remain part of the European Medicines Agency is a promising sign that this could be simpler than previously thought.
"We trust that the ongoing talks between the UK and EU will be constructive and keep patients at the forefront of discussions, ensuring access to new medicines is not delayed and the huge efforts towards pharmacovigilance harmonisation, improving patient safety, are not undone. It is possible, however, that the UK will walk away from the negotiating table with no deal and no arrangements, transitional or otherwise, for the continued co-operation on the regulation of medicines and PV.
"Quanticate will continue to monitor developments through the close involvement of our highly experienced PV team with expert industry bodies and frequent interactions with regulatory agencies. Quanticate will ensure rapid responses to the changing regulatory landscape to minimise the impact of Brexit for existing and new clients. Our EU offices also have us well placed for any necessary transition of activities in the short or longer term."
David has a PhD in Cell Physiology and Biophysics and 15 years’ experience in the pharmaceutical industry, with more than 14 years working in the pharmacovigilance sector. David has worked in small, medium-size and large specialty pharma/biotech companies and has gained pre- and post-marketing experience in a range of therapeutic areas including gastroenterology, hepatology, neurology, oncology and psychiatric conditions as well as advanced therapy medicinal products (ATMPs) and orphan drug indication products for rare diseases. Since 2015, David has worked in the specialist pharmacovigilance service provider sector, leading multiple large teams responsible for clinical and post-marketing for Customers ranging from small pharma/biotech to large specialty and generic companies before joining Quanticate in 2018.
Related News
-
News Eli Lilly gets ready to launch five new drugs in 2023
Eli Lilly, the American pharmaceutical company (IN, USA) are gearing up for a big year ahead, with hopes to launch five new drugs and capitalise on growing obesity and Alzheimer’s disease markets. -
News Amgen buys Horizon for $27.8 billion in bold step into the rare disease market
Amgen Inc buys pharmaceutical company Horizon Therapeutics in a multibillion-dollar deal, in hopes to capitalise on it's portfolio of drugs in the highly sort after rare disease market. -
News Pharma Supply Chain People Moves
The latest appointments and promotions across the pharmaceutical supply chain. -
News Merck to donate new Ebola vaccine to defend against outbreaks in Uganda
Pharmaceutical giant Merck has announced they will be speeding up the processing of a new vaccine against the latest strain of the Ebola virus, to be donated to a global non-profit organisation for distribution -
News CPHI Podcast Series: Driving innovation with pharmaceutical startups
The latest episode in the CPHI Podcast Series explores how startups are driving innovation by taking high-risk approaches and doing business with greater agility. -
News Greener and efficient processes: Quaternary Ammonium Salts
Quaternary Ammonium Salts play a crucial part in Organic Chemistry processes at many major industries. Discover why.
-
News Biosimilars save patients $11B annually, but barriers to adoption remain in US market
Biosimilars introduce competition into the biologics market, driving down prices and increasing patient access. -
News WHO recommends use of two monoclonal antibody treatments against Ebola
The health body recommended use of treatments by Regeneron and Ridgeback Bio
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance